154 related articles for article (PubMed ID: 9834102)
21. Combinational FLt3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy.
Berhanu A; Huang J; Alber SM; Watkins SC; Storkus WJ
Cancer Res; 2006 May; 66(9):4895-903. PubMed ID: 16651446
[TBL] [Abstract][Full Text] [Related]
22. Sustained and NK/CD4+ T cell-dependent efficient prevention of lung metastasis induced by dendritic cells harboring recombinant Sendai virus.
Komaru A; Ueda Y; Furuya A; Tanaka S; Yoshida K; Kato T; Kinoh H; Harada Y; Suzuki H; Inoue M; Hasegawa M; Ichikawa T; Yonemitsu Y
J Immunol; 2009 Oct; 183(7):4211-9. PubMed ID: 19734206
[TBL] [Abstract][Full Text] [Related]
23. Interleukin-2: developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity.
Lotze MT; Shurin M; Esche C; Tahara H; Storkus W; Kirkwood JM; Whiteside TL; Elder EM; Okada H; Robbins P
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S61-6. PubMed ID: 10685662
[TBL] [Abstract][Full Text] [Related]
24. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
25. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
26. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
27. Augmentation of in vitro interleukin 10 production after in vivo administration of interleukin 18 is activated macrophage-dependent and is probably not involved in the antitumor effects of interleukin 18.
Micallef MJ; Tanimoto T; Kohno K; Ikeda M; Ikegami H; Kurimoto M
Anticancer Res; 1998; 18(6A):4267-74. PubMed ID: 9891477
[TBL] [Abstract][Full Text] [Related]
28. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor.
van Herpen CM; van der Laak JA; de Vries IJ; van Krieken JH; de Wilde PC; Balvers MG; Adema GJ; De Mulder PH
Clin Cancer Res; 2005 Mar; 11(5):1899-909. PubMed ID: 15756016
[TBL] [Abstract][Full Text] [Related]
29. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
[TBL] [Abstract][Full Text] [Related]
30. Flt-3 ligand inhibits growth of human ovarian tumors engrafted in severe combined immunodeficient mice.
Silver DF; Hempling RE; Piver MS; Repasky EA
Gynecol Oncol; 2000 Jun; 77(3):377-82. PubMed ID: 10831345
[TBL] [Abstract][Full Text] [Related]
31. Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity.
Guo J; Wang B; Zhang M; Chen T; Yu Y; Regulier E; Homann HE; Qin Z; Ju DW; Cao X
Gene Ther; 2002 Jun; 9(12):793-803. PubMed ID: 12040461
[TBL] [Abstract][Full Text] [Related]
32. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts.
Zitvogel L; Tahara H; Robbins PD; Storkus WJ; Clarke MR; Nalesnik MA; Lotze MT
J Immunol; 1995 Aug; 155(3):1393-403. PubMed ID: 7636204
[TBL] [Abstract][Full Text] [Related]
33. AsGM1+ NK cells prevent metastasis of invading LD-MCA-38 tumor cells in the nude mouse.
Volpe CM; Mehta N; Kim U; Hordines J; Doerr RJ; Cohen SA
J Surg Res; 1999 Jun; 84(2):157-61. PubMed ID: 10357913
[TBL] [Abstract][Full Text] [Related]
34. Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity.
Hwang KS; Cho WK; Yoo J; Seong YR; Kim BK; Kim S; Im DS
Cancer Gene Ther; 2004 Jun; 11(6):397-407. PubMed ID: 15044962
[TBL] [Abstract][Full Text] [Related]
35. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Lafreniere R; Rosenberg SA
J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
[TBL] [Abstract][Full Text] [Related]
36. Augmentation of dendritic cells in murine organ donors by Flt3 ligand alters the balance between transplant tolerance and immunity.
Steptoe RJ; Fu F; Li W; Drakes ML; Lu L; Demetris AJ; Qian S; McKenna HJ; Thomson AW
J Immunol; 1997 Dec; 159(11):5483-91. PubMed ID: 9548488
[TBL] [Abstract][Full Text] [Related]
37. Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice.
Mulé JJ; Custer MC; Travis WD; Rosenberg SA
J Immunol; 1992 Apr; 148(8):2622-9. PubMed ID: 1348521
[TBL] [Abstract][Full Text] [Related]
38. Interleukin 12 augments the liver-associated immunity and reduces liver metastases.
Okuno K; Jinnai H; Lee YS; Kaneda K; Yasutomi M
Hepatogastroenterology; 1996; 43(11):1196-202. PubMed ID: 8908551
[TBL] [Abstract][Full Text] [Related]
39. Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues.
Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA
J Immunol; 1985 Aug; 135(2):1488-97. PubMed ID: 3891854
[TBL] [Abstract][Full Text] [Related]
40. Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000.
Nakagawa R; Motoki K; Ueno H; Iijima R; Nakamura H; Kobayashi E; Shimosaka A; Koezuka Y
Cancer Res; 1998 Mar; 58(6):1202-7. PubMed ID: 9515806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
